These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 9288779

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
    Morrissey JJ, Raney S.
    Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Binding analysis of the estrogen receptor to its specific DNA target site in human breast cancer.
    Foster BD, Cavener DR, Parl FF.
    Cancer Res; 1991 Jul 01; 51(13):3405-10. PubMed ID: 2054780
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H, Arteaga CL.
    Clin Cancer Res; 2001 Dec 01; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [Abstract] [Full Text] [Related]

  • 8. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, Frandsen T, Spang-Thomsen M, Fuqua SA, Clarke R.
    Cancer Res; 1997 Aug 15; 57(16):3486-93. PubMed ID: 9270017
    [Abstract] [Full Text] [Related]

  • 9. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.
    J Natl Cancer Inst; 2005 Sep 07; 97(17):1254-61. PubMed ID: 16145046
    [Abstract] [Full Text] [Related]

  • 10. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
    Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA.
    Oncogene; 2003 Oct 20; 22(47):7316-39. PubMed ID: 14576841
    [Abstract] [Full Text] [Related]

  • 11. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.
    Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, Gustafsson JA, Rochefort H.
    Clin Cancer Res; 2004 Sep 01; 10(17):5769-76. PubMed ID: 15355905
    [Abstract] [Full Text] [Related]

  • 12. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
    Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA.
    Clin Cancer Res; 2004 Nov 15; 10(22):7490-9. PubMed ID: 15569979
    [Abstract] [Full Text] [Related]

  • 13. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M.
    Cancer Res; 2002 Sep 01; 62(17):4977-84. PubMed ID: 12208749
    [Abstract] [Full Text] [Related]

  • 14. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
    Gökmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, Shen C, Bruckheimer E, Kinch MS, Miller KD.
    Breast Cancer Res Treat; 2011 Jun 01; 127(2):375-84. PubMed ID: 20602165
    [Abstract] [Full Text] [Related]

  • 15. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC.
    Endocr Relat Cancer; 2005 Jul 01; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [Abstract] [Full Text] [Related]

  • 16. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR, Boeddinghaus IM, Riddler S, Haynes BP, Hardcastle IR, Rowlands M, Grimshaw R, Jarman M, Dowsett M.
    Cancer Res; 1999 Aug 01; 59(15):3646-51. PubMed ID: 10446976
    [Abstract] [Full Text] [Related]

  • 17. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
    Bachmann-Moisson N, Barberi-Heyob M, Merlin JL, Ledrich ML, Batt AM, Guillemin F.
    Bull Cancer; 1996 Oct 01; 83(10):808-15. PubMed ID: 8952630
    [Abstract] [Full Text] [Related]

  • 18. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
    Girault I, Bièche I, Lidereau R.
    Maturitas; 2006 Jul 20; 54(4):342-51. PubMed ID: 16822624
    [Abstract] [Full Text] [Related]

  • 19. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity.
    Pavlik EJ, Nelson K, Srinivasan S, Powell DE, Kenady DE, DePriest PD, Gallion HH, van Nagell JR.
    Cancer Res; 1992 Aug 01; 52(15):4106-12. PubMed ID: 1638522
    [Abstract] [Full Text] [Related]

  • 20. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC, O'Regan RM, Gajdos C, Robinson SP, Bentrem D, De Los Reyes A, Jordan VC.
    Clin Cancer Res; 2002 Jun 01; 8(6):1995-2001. PubMed ID: 12060645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.